Saturday 17 October 2026
Export GDRX’s income statement to Excel — free account
GoodRx Holdings, Inc.
GDRX Healthcare Health Information Services
GoodRx Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $796.9 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 1.31%, EPS fell 25.0%, free cash flow grew 112.5% and total debt was flat, each against the same quarter a year earlier.
3.36
0.15
−4.27%
Follow GDRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
53.73 | 30.82 | 30.04 | 45.39 |
+8 more quarters Free account |
P/S ratio |
1.24 | 0.85 | 1.21 | 1.83 | |
P/FCF ratio |
7.42 | 6.91 | 10.29 | 13.98 | |
P/Operating CF |
12.09 | 56.38 | 29.36 | 19.30 | |
P/B ratio |
1.51 | 1.07 | 1.57 | 2.44 | |
Price to Tangible BV |
6.14 | 5.12 | 7.92 | 12.62 | |
EV/Sales |
1.49 | 1.17 | 1.50 | 2.10 | |
EV/EBITDA |
7.06 | 5.54 | 6.83 | 10.14 | |
EV/Operating CF |
5.79 | 5.40 | 7.10 | 9.36 | |
EV/FCF |
8.87 | 9.52 | 12.70 | 16.03 | |
Quick Ratio |
0.41 | 0.55 | 2.02 | 2.62 | |
Current Ratio |
1.38 | 1.47 | 2.61 | 3.11 | |
Net Debt/EBITDA |
4.11 | 6.94 | 4.89 | 5.91 | |
Debt/Assets |
20.77% | 24.11% | 34.78% | 36.90% | |
Debt/Equity |
0.75 | 0.78 | 0.79 | 0.81 | |
Asset Turnover |
0.43 | 0.48 | 0.57 | 0.60 | |
Operating CF/Net income |
9.47 | 10.13 | 6.06 | 67.94 | |
Capex/Depreciation |
(0.63) | (0.97) | (0.67) | (0.82) | |
Interest Coverage |
2.41 | 1.43 | 2.18 | 1.35 | |
Research and Development Expense of Revenue |
13.33% | 15.55% | 14.86% | 15.82% | |
Selling, General and Administrative Expense of Revenue |
53.29% | 55.60% | 52.65% | 58.94% | |
Intangible Assets out of Total Assets |
0.21 | 0.24 | 0.35 | 0.37 | |
Share Based Compensation of Revenue |
8.28% | 8.51% | 9.20% | 9.24% | |
Graham Net Nets |
(0.10) | (0.20) | (0.15) | (0.11) | |
Graham Number |
1.52 | 1.62 | 1.87 | 1.91 | |
Earnings Yield |
1.86% | 3.24% | 3.33% | 2.20% | |
Free Cash Flow Yield |
13.48% | 14.46% | 9.72% | 7.15% | |
Revenue per Share |
0.59 | 0.57 | 0.55 | 0.57 | |
Operating CF per Share |
0.24 | 0.03 | 0.09 | 0.22 | |
Capex per Share |
(0.04) | (0.06) | (0.04) | (0.05) | |
Free Cash Flow per Share |
0.20 | (0.03) | 0.05 | 0.17 | |
Cash per Share |
0.87 | 0.69 | 0.73 | 0.79 | |
Shareholders Equity per Share |
1.91 | 1.83 | 1.73 | 1.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.91 | 1.83 | 1.73 | 1.73 | |
Free Cash Flow |
66.42 | (9.81) | 17.06 | 58.02 | |
Working Capital |
441.46 | 407.27 | 397.10 | 383.66 | |
Capital Expenditures |
(14.41) | (21.64) | (15.83) | (18.00) | |
Net Current Asset Value |
(96.00) | (132.80) | (144.69) | (159.28) | |
EV/EBIT |
15.58 | 11.77 | 13.63 | 20.27 | |
Capex to Sales |
0.07 | 0.11 | 0.08 | 0.09 | |
Price to Operating Income |
13.04 | 8.54 | 11.04 | 17.68 | |
| Other line items | |||||
Average Receivables |
185.58 | 196.42 | 190.84 | 167.27 | |
Average Payables |
17.16 | 14.89 | 16.77 | 20.56 | |
Average Assets |
1,830.82 | 1,658.26 | 1,396.06 | 1,340.18 | |
Average Common Equity |
645.32 | 638.17 | 670.46 | 648.57 |
Columns are period end dates